InMed's INM-901: A Promising Preclinical Alzheimer's Disease Treatment

InMed Pharmaceuticals Inc. (NASDAQ: INM) has announced positive results from a long-term in vivo preclinical Alzheimer's Disease ('AD') study of its proprietary small molecule drug candidate, INM-901. The drug demonstrated a significant reduction in several plasma and brain markers of neuroinflammation, a recognized contributor to AD development and progression. This article explores the implications of these findings and the potential of INM-901 as a promising treatment for Alzheimer's disease.



In the study, INM-901 showed a dose-dependent and statistically significant reduction in plasma pro-inflammatory cytokines such as TNF-α, IL-1β, and INF-γ. These cytokines play a crucial role in cell-to-cell communication and regulating the immune response, and their reduction may slow or mitigate the inflammatory process, preventing neurodegeneration and the progression of AD (InMed Pharmaceuticals, January 21, 2025). Additionally, INM-901 demonstrated a significant reduction in neurofilament light chain ('NfL'), a neurodegeneration biomarker, in the plasma for the high dose treated group. NfL is a protein released from neurons in response to injury or disease, and its reduction indicates a decrease in neuronal damage and cellular stress.

Moreover, mRNA assessments showed a reduction of several key neuroinflammatory genes in the brain, such as GFAP, CD-33, and TLR-2. These findings further support the overall results from the study, indicating that INM-901 may lower neuroinflammation, which is a recognized contributor to AD development and progression (InMed Pharmaceuticals, January 21, 2025). The reduction of these genes suggests that INM-901 may help mitigate astrogliosis, decrease microglial activation, and alleviate the activation of the immune system in the brain, which could help alleviate neuroinflammation and prevent further neuronal damage.

Dr. Eric Hsu, InMed's SVP of Preclinical R&D, commented on the data, stating, "We are highly encouraged by the data from our long-term preclinical study of INM-901. Overall, our data showed a reduction of several neuroinflammation markers in an amyloid-induced Alzheimer's disease model, suggesting that INM-901 may lower neuroinflammation. The ability of INM-901 to actively reduce inflammation is an exciting development, as neuroinflammation has emerged as a promising new drug target beyond existing AD treatments focused primarily on removing amyloid beta plaques and tau protein tangles."



INM-901's key characteristics include oral administration capability, demonstrated neuroprotective effects through CB1/CB2 receptor activation, and impact on PPARs. The company is conducting additional analyses focusing on receptor engagement levels, neuritogenesis, and neuroprotection, with results expected in the coming weeks. These analyses will help better define the mechanisms of action and potential role of INM-901 in AD treatment.

In conclusion, InMed Pharmaceuticals' INM-901 has shown promising results in a long-term preclinical Alzheimer's disease study, demonstrating a significant reduction in neuroinflammation markers and neurodegeneration biomarkers. These findings suggest that INM-901 may have the potential to address multiple pathological factors associated with AD, making it a very promising drug candidate for the treatment of this devastating condition. As the company continues to advance its preclinical studies and develop the chemistry, manufacturing, and controls (CMC) for drug substance and oral drug product formulation, investors should keep a close eye on INM-901's progress and its potential impact on the Alzheimer's disease market.